• Something wrong with this record ?

Thrombotic and Atherogenetic Predisposition in Polyglobulic Donors

N. Slaninova, I. Bryjova, Z. Lasota, R. Richterova, J. Kubicek, M. Augustynek, A. Seal, O. Krejcar, A. Proto

. 2022 ; 10 (4) : . [pub] 20220412

Language English Country Switzerland

Document type Journal Article

This work analyses the results of research regarding the predisposition of genetic hematological risks associated with secondary polyglobulia. The subjects of the study were selected based on shared laboratory markers and basic clinical symptoms. JAK2 (Janus Kinase 2) mutation negativity represented the common genetic marker of the subjects in the sample of interest. A negative JAK2 mutation hypothetically excluded the presence of an autonomous myeloproliferative disease at the time of detection. The parameters studied in this work focused mainly on thrombotic, immunological, metabolic, and cardiovascular risks. The final goal of the work was to discover the most significant key markers for the diagnosis of high-risk patients and to exclude the less important or only complementary markers, which often represent a superfluous economic burden for healthcare institutions. These research results are applicable as a clinical guideline for the effective diagnosis of selected parameters that demonstrated high sensitivity and specificity. According to the results obtained in the present research, groups with a high incidence of mutations were evaluated as being at higher risk for polycythemia vera disease. It was not possible to clearly determine which of the patients examined had a higher risk of developing the disease as different combinations of mutations could manifest different symptoms of the disease. In general, the entire study group was at risk for manifestations of polycythemia vera disease without a clear diagnosis. The group with less than 20% incidence appeared to be clinically insignificant for polycythemia vera testing and thus there is a potential for saving money in mutation testing. On the other hand, the JAK V617F (somatic mutation of JAK2) parameter from this group should be investigated as it is a clear exclusion or confirmation of polycythemia vera as the primary disease.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22017382
003      
CZ-PrNML
005      
20220720100216.0
007      
ta
008      
220718s2022 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/biomedicines10040888 $2 doi
035    __
$a (PubMed)35453637
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Slaninova, Nikola $u Department of Cybernetics and Biomedical Engineering, VŠB-Technical University of Ostrava, 17. listopadu 2172/15, 708 00 Ostrava-Poruba, Czech Republic
245    10
$a Thrombotic and Atherogenetic Predisposition in Polyglobulic Donors / $c N. Slaninova, I. Bryjova, Z. Lasota, R. Richterova, J. Kubicek, M. Augustynek, A. Seal, O. Krejcar, A. Proto
520    9_
$a This work analyses the results of research regarding the predisposition of genetic hematological risks associated with secondary polyglobulia. The subjects of the study were selected based on shared laboratory markers and basic clinical symptoms. JAK2 (Janus Kinase 2) mutation negativity represented the common genetic marker of the subjects in the sample of interest. A negative JAK2 mutation hypothetically excluded the presence of an autonomous myeloproliferative disease at the time of detection. The parameters studied in this work focused mainly on thrombotic, immunological, metabolic, and cardiovascular risks. The final goal of the work was to discover the most significant key markers for the diagnosis of high-risk patients and to exclude the less important or only complementary markers, which often represent a superfluous economic burden for healthcare institutions. These research results are applicable as a clinical guideline for the effective diagnosis of selected parameters that demonstrated high sensitivity and specificity. According to the results obtained in the present research, groups with a high incidence of mutations were evaluated as being at higher risk for polycythemia vera disease. It was not possible to clearly determine which of the patients examined had a higher risk of developing the disease as different combinations of mutations could manifest different symptoms of the disease. In general, the entire study group was at risk for manifestations of polycythemia vera disease without a clear diagnosis. The group with less than 20% incidence appeared to be clinically insignificant for polycythemia vera testing and thus there is a potential for saving money in mutation testing. On the other hand, the JAK V617F (somatic mutation of JAK2) parameter from this group should be investigated as it is a clear exclusion or confirmation of polycythemia vera as the primary disease.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Bryjova, Iveta $u Department of Cybernetics and Biomedical Engineering, VŠB-Technical University of Ostrava, 17. listopadu 2172/15, 708 00 Ostrava-Poruba, Czech Republic
700    1_
$a Lasota, Zenon $u Blood Donor Center, tr. T. G. Masaryka 495, 738 01 Frydek-Mistek, Czech Republic
700    1_
$a Richterova, Radmila $u Blood Donor Center, tr. T. G. Masaryka 495, 738 01 Frydek-Mistek, Czech Republic
700    1_
$a Kubicek, Jan $u Department of Cybernetics and Biomedical Engineering, VŠB-Technical University of Ostrava, 17. listopadu 2172/15, 708 00 Ostrava-Poruba, Czech Republic
700    1_
$a Augustynek, Martin $u Department of Cybernetics and Biomedical Engineering, VŠB-Technical University of Ostrava, 17. listopadu 2172/15, 708 00 Ostrava-Poruba, Czech Republic $1 https://orcid.org/0000000201657317 $7 ola2011639627
700    1_
$a Seal, Ayan $u Department of Computer Science & Engineering, PDPM Indian Institute of Information Technology, Design and Manufacturing, Jabalpur 482005, India $u Center for Basic and Applied Research, Faculty of Informatics and Management, University of Hradec Kralove, Hradecka 1249, 500 03 Hradec Kralove, Czech Republic $1 https://orcid.org/0000000299392926
700    1_
$a Krejcar, Ondrej $u Center for Basic and Applied Research, Faculty of Informatics and Management, University of Hradec Kralove, Hradecka 1249, 500 03 Hradec Kralove, Czech Republic $1 https://orcid.org/0000000259922574
700    1_
$a Proto, Antonino $u Department of Cybernetics and Biomedical Engineering, VŠB-Technical University of Ostrava, 17. listopadu 2172/15, 708 00 Ostrava-Poruba, Czech Republic $1 https://orcid.org/0000000319648184
773    0_
$w MED00205373 $t Biomedicines $x 2227-9059 $g Roč. 10, č. 4 (2022)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35453637 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20220718 $b ABA008
991    __
$a 20220720100211 $b ABA008
999    __
$a ind $b bmc $g 1816566 $s 1168624
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 10 $c 4 $e 20220412 $i 2227-9059 $m Biomedicines $n Biomedicines $x MED00205373
LZP    __
$a Pubmed-20220718

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...